Pharmadrug Stock Net Income
| LMLLF Stock | USD 0.01 0.0006 5.56% |
As of the 25th of January, Pharmadrug holds the Semi Deviation of 14.3, coefficient of variation of 762.37, and Risk Adjusted Performance of 0.1056. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pharmadrug, as well as the relationship between them. Please check Pharmadrug coefficient of variation and the relationship between the jensen alpha and skewness to decide if Pharmadrug is priced some-what accurately, providing market reflects its current price of 0.0114 per share. As Pharmadrug appears to be a penny stock we also advise to check out its total risk alpha numbers.
Pharmadrug's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pharmadrug's valuation are provided below:Pharmadrug does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Pharmadrug |
Pharmadrug 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pharmadrug's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pharmadrug.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Pharmadrug on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Pharmadrug or generate 0.0% return on investment in Pharmadrug over 90 days. Pharmadrug Inc. operates as a specialty pharmaceutical company More
Pharmadrug Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pharmadrug's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pharmadrug upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 25.55 | |||
| Information Ratio | 0.1269 | |||
| Maximum Drawdown | 99.3 | |||
| Value At Risk | (34.78) | |||
| Potential Upside | 34.62 |
Pharmadrug Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmadrug's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pharmadrug's standard deviation. In reality, there are many statistical measures that can use Pharmadrug historical prices to predict the future Pharmadrug's volatility.| Risk Adjusted Performance | 0.1056 | |||
| Jensen Alpha | 2.33 | |||
| Total Risk Alpha | 0.6793 | |||
| Sortino Ratio | 0.0905 | |||
| Treynor Ratio | 2.92 |
Pharmadrug January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1056 | |||
| Market Risk Adjusted Performance | 2.93 | |||
| Mean Deviation | 12.03 | |||
| Semi Deviation | 14.3 | |||
| Downside Deviation | 25.55 | |||
| Coefficient Of Variation | 762.37 | |||
| Standard Deviation | 18.23 | |||
| Variance | 332.3 | |||
| Information Ratio | 0.1269 | |||
| Jensen Alpha | 2.33 | |||
| Total Risk Alpha | 0.6793 | |||
| Sortino Ratio | 0.0905 | |||
| Treynor Ratio | 2.92 | |||
| Maximum Drawdown | 99.3 | |||
| Value At Risk | (34.78) | |||
| Potential Upside | 34.62 | |||
| Downside Variance | 652.91 | |||
| Semi Variance | 204.57 | |||
| Expected Short fall | (18.94) | |||
| Skewness | 0.1672 | |||
| Kurtosis | 1.6 |
Pharmadrug Backtested Returns
Pharmadrug is out of control given 3 months investment horizon. Pharmadrug maintains Sharpe Ratio (i.e., Efficiency) of 0.0978, which implies the firm had a 0.0978 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.69% are justified by taking the suggested risk. Use Pharmadrug Semi Deviation of 14.3, coefficient of variation of 762.37, and Risk Adjusted Performance of 0.1056 to evaluate company specific risk that cannot be diversified away. Pharmadrug holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of 0.81, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pharmadrug's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pharmadrug is expected to be smaller as well. Use Pharmadrug potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to analyze future returns on Pharmadrug.
Auto-correlation | 0.17 |
Very weak predictability
Pharmadrug has very weak predictability. Overlapping area represents the amount of predictability between Pharmadrug time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pharmadrug price movement. The serial correlation of 0.17 indicates that over 17.0% of current Pharmadrug price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | -0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Pharmadrug reported net income of (5.63 Million). This is 101.65% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.99% higher than that of the company.
Pharmadrug Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmadrug's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharmadrug could also be used in its relative valuation, which is a method of valuing Pharmadrug by comparing valuation metrics of similar companies.Pharmadrug is currently under evaluation in net income category among its peers.
Pharmadrug Fundamentals
| Return On Equity | -0.59 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.08) % | |||
| Current Valuation | 4.43 M | |||
| Shares Outstanding | 355.63 M | |||
| Shares Owned By Insiders | 1.88 % | |||
| Price To Book | 0.55 X | |||
| Price To Sales | 7.86 X | |||
| Revenue | 494.99 K | |||
| Gross Profit | 182.04 K | |||
| EBITDA | (5.27 M) | |||
| Net Income | (5.63 M) | |||
| Cash And Equivalents | 126.38 K | |||
| Total Debt | 786.37 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 2.69 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (4.13 M) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 2.94 | |||
| Market Capitalization | 3.97 M | |||
| Total Asset | 19.52 M | |||
| Z Score | 3.0 | |||
| Net Asset | 19.52 M |
About Pharmadrug Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmadrug's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmadrug using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmadrug based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmadrug Pink Sheet
Pharmadrug financial ratios help investors to determine whether Pharmadrug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmadrug with respect to the benefits of owning Pharmadrug security.